Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical insulin eye drops for persistent corneal epithelial defect
IRCT20250513065716N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of human insulin in corneal persistent epithelial defect (PED) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Corneal epithelial defect size. Started Nov 2025; status: completed.
02
Drugs
human insulin
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on IRCT20250513065716N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250513065716N2.